TrialFrontiers in immunology2021

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.

Jiamao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.